Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAB BioAtla	$0.41 +14.2%	$0.37	$0.24 ▼ $2.53	$23.88M	0.9	706,742 shs	1.65 million shs
JMAC Maxpro Capital Acquisition	$6.33 +4.7%	$6.04	$7.50 ▼ $19.22	$85.00M	0.01	74,040 shs	4,674 shs
PYXS Pyxis Oncology	$1.37 -1.4%	$1.16	$0.83 ▼ $5.39	$84.97M	1.13	551,585 shs	223,141 shs
WHWK Whitehawk Therapeutics	$1.81 +6.5%	$1.83	$1.39 ▼ $3.81	$85.31M	0.55	151,426 shs	125,163 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAB BioAtla	-0.06%	-8.39%	+0.34%	-6.64%	-81.16%
JMAC Maxpro Capital Acquisition	0.00%	+6.61%	-2.98%	-14.62%	+4,280.14%
PYXS Pyxis Oncology	+3.73%	+12.10%	+11.20%	+12.10%	-62.53%
WHWK Whitehawk Therapeutics	-2.30%	+5.59%	-12.82%	+169,999,900.00%	+169,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCAB BioAtla	1.9706 of 5 stars	3.0	3.0	0.0	0.0	0.6	2.5	0.6
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PYXS Pyxis Oncology	2.2642 of 5 stars	3.3	2.0	0.0	0.0	3.3	0.8	0.6
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAB BioAtla	2.00	Hold	$5.00	1,129.71% Upside
JMAC Maxpro Capital Acquisition	0.00	N/A	N/A	N/A
PYXS Pyxis Oncology	2.60	Moderate Buy	$8.67	532.60% Upside
WHWK Whitehawk Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest BCAB, PYXS, WHWK, and JMAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	PYXS Pyxis Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
8/18/2025	PYXS Pyxis Oncology	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/13/2025	BCAB BioAtla	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
8/13/2025	BCAB BioAtla	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/11/2025	WHWK Whitehawk Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell

(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAB BioAtla	$11M	2.17	N/A	N/A	$0.25 per share	1.63
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
PYXS Pyxis Oncology	$16.15M	5.26	N/A	N/A	$2.03 per share	0.67
WHWK Whitehawk Therapeutics	$25.98M	3.28	N/A	N/A	$2.12 per share	0.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAB BioAtla	-$69.78M	-$1.10	N/A	N/A	N/A	N/A	-1,177.18%	-137.51%	11/6/2025 (Estimated)
JMAC Maxpro Capital Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PYXS Pyxis Oncology	-$77.33M	-$1.60	N/A	N/A	N/A	N/A	-68.56%	-52.14%	11/11/2025 (Estimated)
WHWK Whitehawk Therapeutics	-$63.69M	-$0.06	N/A	∞	N/A	99.42%	-75.99%	-68.57%	N/A

Latest BCAB, PYXS, WHWK, and JMAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PYXS Pyxis Oncology	-$0.36	-$0.30	+$0.06	-$0.30	N/A	$2.82 million
8/7/2025	Q2 2025	BCAB BioAtla	-$0.29	-$0.31	-$0.02	-$0.32	N/A	N/A
8/7/2025	Q2 2025	WHWK Whitehawk Therapeutics	$0.49	-$0.76	-$1.25	-$0.76	$100.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAB BioAtla	N/A	N/A	N/A	N/A	N/A
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
PYXS Pyxis Oncology	N/A	N/A	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAB BioAtla	N/A	1.24	1.24
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A
PYXS Pyxis Oncology	N/A	5.65	5.65
WHWK Whitehawk Therapeutics	N/A	20.41	20.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAB BioAtla	77.23%
JMAC Maxpro Capital Acquisition	73.18%
PYXS Pyxis Oncology	39.09%
WHWK Whitehawk Therapeutics	52.08%

Insider Ownership

Company	Insider Ownership
BCAB BioAtla	11.22%
JMAC Maxpro Capital Acquisition	19.27%
PYXS Pyxis Oncology	10.60%
WHWK Whitehawk Therapeutics	49.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAB BioAtla	60	58.72 million	52.13 million	Optionable
JMAC Maxpro Capital Acquisition	2,021	13.43 million	10.84 million	Not Optionable
PYXS Pyxis Oncology	60	62.02 million	55.44 million	Optionable
WHWK Whitehawk Therapeutics	40	47.13 million	23.61 million	N/A

BCAB, PYXS, WHWK, and JMAC Headlines

Recent News About These Companies

Whitehawk Therapeutics (NASDAQ:WHWK) Announces Quarterly Earnings Results, Misses Expectations By $1.25 EPS

August 10, 2025 | marketbeat.com

Whitehawk Therapeutics (NASDAQ:WHWK) Downgraded to "Strong Sell" Rating by Wall Street Zen

August 10, 2025 | marketbeat.com

Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

August 7, 2025 | prnewswire.com

Whitehawk Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

July 22, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB, PYXS, WHWK, and JMAC Company Descriptions

BioAtla NASDAQ:BCAB

$0.41 +0.05 (+14.21%)

Closing price 04:00 PM Eastern

Extended Trading

$0.41 +0.00 (+0.84%)

As of 05:23 PM Eastern

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

Maxpro Capital Acquisition NASDAQ:JMAC

$6.33 +0.29 (+4.72%)

As of 08/25/2025

Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.

Pyxis Oncology NASDAQ:PYXS

$1.37 -0.02 (-1.44%)

Closing price 04:00 PM Eastern

Extended Trading

$1.37 0.00 (0.00%)

As of 04:39 PM Eastern

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Whitehawk Therapeutics NASDAQ:WHWK

$1.81 +0.11 (+6.47%)

As of 04:00 PM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time